A Randomized, Single-Blind, Group Sequential, Active-Controlled Study to Evaluate the Clinical Efficacy and Safety of α-Lipoic Acid for Critically Ill Patients With Coronavirus Disease 2019 (COVID-19).

Front Med (Lausanne) · 2021 · PMC8854372 · PMID 35186959

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

The results suggested ALA treatment might be able to improve 30-day survival rate of patients with critically ill COVID-19 and slow down the increase of SOFA score, both parameters did not reach statistical significance due to the limited patient number, but the tendency of improvement is clear to see.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.